Renal insufficiency has been associated with an increased risk of adverse effects with many
classes of medications. The risk of some, but not all, adverse effects has been linked to the …

The clinical pharmacokinetics and in vitro inhibition of digoxin were examined to predict the
P‐glycoprotein (P‐gp) component of drug–drug interactions. Coadministered drugs (co …

Principles of Clinical Pharmacology is a successful survey covering the pharmacologic
principles underlying the individualization of patient therapy and contemporary drug …

Regular performance of medication reviews is prominent among methods that have been
advocated to reduce the extent and seriousness of drug-related problems, such as adverse …

Objectives. This study sought to examine the hemodynamic and autonomic dose response
to digoxin. Background. Previous studies have demonstrated an increase in contractility and …

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug–
drug interactions between digoxin and P-gp inhibitors (eg verapamil and its metabolite …

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated
drug–drug interactions (DDIs) in vivo. The overall aim of our study was to investigate the …

The objective of this work was to further investigate the reasons for disconcordant clinical
digoxin drug interactions (DDIs) particularly for false negative where in vitro data suggests …

Background Serum digoxin concentrations (SDCs) are frequently sampled before
completion of drug distribution. If elevated, these concentrations may be misinterpreted …

PURPOSE: Although there is renewed enthusiasm for the use of digoxin in patients with
heart failure, current dosing guidelines are based on a nomogram published in 1974. We …